BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma
- Katharine Herbert1,
- Romuald Binet1,16,
- Jean-Philippe Lambert2,3,16,
- Pakavarin Louphrasitthiphol1,
- Halime Kalkavan4,
- Laura Sesma-Sanz5,6,
- Carla Daniela Robles-Espinoza7,8,
- Sovan Sarkar9,
- Eda Suer1,
- Sarah Andrews1,
- Jagat Chauhan1,
- Nicola D. Roberts10,
- Mark R. Middleton9,
- Anne-Claude Gingras2,11,
- Jean-Yves Masson5,6,
- Lionel Larue12,13,14,
- Paola Falletta1,15 and
- Colin R. Goding1
- 1Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom;
- 2Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada;
- 3Department of Molecular Medicine, Cancer Research Centre, Université Laval, Quebec G1V 0A6, Canada; CHU de Québec Research Center, CHUL, Quebec G1V 4G2, Canada;
- 4Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA;
- 5Genome Stability Laboratory, CHU de Oncology Division, Québec Research Center, Québec City, Quebec G1R 3S3, Canada;
- 6Department of Molecular Biology, Medical Biochemistry, and Pathology, Laval University Cancer Research Center, Québec City, Quebec G1V 0A6, Canada;
- 7Laboratorio Internacional de Investigación Sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro 76230, Mexico;
- 8Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, United Kingdom;
- 9Department of Oncology, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom;
- 10The Cancer Genome Project, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, United Kingdom;
- 11Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 1A8, Canada;
- 12Institut Curie, PSL Research University, Normal and Pathological Development of Melanocytes, U1021, Institut National de la Santé et de la Recherche Médicale (INSERM), 91405 Orsay, France;
- 13University Paris-Sud, University Paris-Saclay, UMR 3347, Centre National de la Recherche Scientifique (CNRS), 91505 Orsay, France;
- 14Equipe Labellisée Ligue Contre le Cancer, 91405 Orsay, France;
- 15Università Vita-Salute San Raffaele, Milano, 20132 Milano MI, Italy
- Corresponding authors: colin.goding{at}ludwig.ox.ac.uk, falletta.paola{at}hsr.it, lionel.larue{at}curie.fr
-
↵16 These authors contributed equally to this work.
Abstract
Whether cell types exposed to a high level of environmental insults possess cell type-specific prosurvival mechanisms or enhanced DNA damage repair capacity is not well understood. BRN2 is a tissue-restricted POU domain transcription factor implicated in neural development and several cancers. In melanoma, BRN2 plays a key role in promoting invasion and regulating proliferation. Here we found, surprisingly, that rather than interacting with transcription cofactors, BRN2 is instead associated with DNA damage response proteins and directly binds PARP1 and Ku70/Ku80. Rapid PARP1-dependent BRN2 association with sites of DNA damage facilitates recruitment of Ku80 and reprograms DNA damage repair by promoting Ku-dependent nonhomologous end-joining (NHEJ) at the expense of homologous recombination. BRN2 also suppresses an apoptosis-associated gene expression program to protect against UVB-, chemotherapy- and vemurafenib-induced apoptosis. Remarkably, BRN2 expression also correlates with a high single-nucleotide variation prevalence in human melanomas. By promoting error-prone DNA damage repair via NHEJ and suppressing apoptosis of damaged cells, our results suggest that BRN2 contributes to the generation of melanomas with a high mutation burden. Our findings highlight a novel role for a key transcription factor in reprogramming DNA damage repair and suggest that BRN2 may impact the response to DNA-damaging agents in BRN2-expressing cancers.
Keywords
Footnotes
-
Supplemental material is available for this article.
-
Article published online ahead of print. Article and publication date are online at http://www.genesdev.org/cgi/doi/10.1101/gad.314633.118.
-
Freely available online through the Genes & Development Open Access option.
- Received March 21, 2018.
- Accepted January 4, 2019.
This article, published in Genes & Development, is available under a Creative Commons License (Attribution 4.0 International), as described at http://creativecommons.org/licenses/by/4.0/.










